Tag: Lantus

Lantus insulin: Insulin glargine, a long-acting insulin analog used by both type 1 and type 2 diabetics to help control blood sugar throughout the day.

Articles

Type 2 diabetes increases breast cancer risk

News

10/08/17: Use of metformin linked to lower recurrence among older BC survivors

Studies

Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production Cite
ter Braak B, Siezen CL, Lee JS, Rao P, Voorhoeve C, Ruppin E, et al. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0802-0
Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes Cite
Wu JW, Azoulay L, Majdan A, Boivin J, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3647-3653 10.1200/jco.2017.73.4491
Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes Cite
Gallagher EJ, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia. Springer Science and Business Media LLC; 2016; 59:2018-2025 10.1007/s00125-016-4000-x
Insulin glargine use and breast cancer risk: Associations with cumulative exposure Cite
Peeters PJHL, Bazelier MT, Leufkens HGM, Auvinen A, van Staa TP, de Vries F, et al. Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncologica. Informa UK Limited; 2016; 55:851-858 10.3109/0284186x.2016.1155736
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study Cite
Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:709-720 10.1007/s10552-016-0744-3
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence Cite
Bronsveld HK, ter Braak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0611-2
Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden Cite
Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:769-777 10.1007/s10552-012-9946-5
The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes Cite
Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes. Elsevier BV; 2012; 6:53-59 10.1016/j.pcd.2011.10.004
Long-term effects of insulin glargine on the risk of breast cancer Cite
Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. Springer Science and Business Media LLC; 2011; 54:2254-2262 10.1007/s00125-011-2190-9